Cancer treatments

Results: 1984



#Item
51VAXIMM Appoints Pharmaceutical Industry Veteran Dr. Jarl Ulf Jungnelius as Chief Medical Officer Basel (Switzerland) and Mannheim (Germany), May 18, 2016 – VAXIMM AG, a Swiss-German biotech company focused on developin

VAXIMM Appoints Pharmaceutical Industry Veteran Dr. Jarl Ulf Jungnelius as Chief Medical Officer Basel (Switzerland) and Mannheim (Germany), May 18, 2016 – VAXIMM AG, a Swiss-German biotech company focused on developin

Add to Reading List

Source URL: www.biomedvc.com

Language: English - Date: 2016-05-18 04:29:39
52DGEpi Nachwuchspreisträger 2010 Es wurden folgende Preise vergeben: 1. Preis Dr. rer. med. Tobias Luck, LIFE Center Universität Leipzig Mild Cognitive Impairment: Incidence and Risk factors – Results of the Leipzig L

DGEpi Nachwuchspreisträger 2010 Es wurden folgende Preise vergeben: 1. Preis Dr. rer. med. Tobias Luck, LIFE Center Universität Leipzig Mild Cognitive Impairment: Incidence and Risk factors – Results of the Leipzig L

Add to Reading List

Source URL: dgepi.de

Language: English - Date: 2014-10-17 03:47:56
53GAP: Phase 2 gemcitabine and nab-paclitaxel for resectable pancreas cancer The GAP trial is helping researchers answer an important health question. It is providing evidence on the benefit of extra chemotherapy treatment

GAP: Phase 2 gemcitabine and nab-paclitaxel for resectable pancreas cancer The GAP trial is helping researchers answer an important health question. It is providing evidence on the benefit of extra chemotherapy treatment

Add to Reading List

Source URL: www.ctc.usyd.edu.au

Language: English - Date: 2016-03-21 19:22:49
54RESEARCHSPOTLIGHT Cancer Therapies, Jaw Bone Necrosis Cancer treatments can save lives, but the devastating effects of some therapies pose new and often significant health hazards for

RESEARCHSPOTLIGHT Cancer Therapies, Jaw Bone Necrosis Cancer treatments can save lives, but the devastating effects of some therapies pose new and often significant health hazards for

Add to Reading List

Source URL: www.dental.upenn.edu

Language: English - Date: 2013-12-04 15:14:41
55Deliverable NoReport on the clinical adaptation and optimization of the Oncosimulator models. In silico studies. Grant Agreement No.:

Deliverable NoReport on the clinical adaptation and optimization of the Oncosimulator models. In silico studies. Grant Agreement No.:

Add to Reading List

Source URL: p-medicine.eu

Language: English - Date: 2014-02-20 04:52:20
56THE ULTIMATE GUIDE TO VITAMIN B-17 METABOLIC THERAPY Published by Worldwithoutcancer.org.uk

THE ULTIMATE GUIDE TO VITAMIN B-17 METABOLIC THERAPY Published by Worldwithoutcancer.org.uk

Add to Reading List

Source URL: www.thelibertyman.com

Language: English - Date: 2013-10-16 14:53:33
57Microsoft Word - PJ Final version May 09amended for printing.doc

Microsoft Word - PJ Final version May 09amended for printing.doc

Add to Reading List

Source URL: www.gutsy-group.org.uk

Language: English - Date: 2016-06-13 14:14:29
58Coverage For Tobacco Use Cessation Treatments

Coverage For Tobacco Use Cessation Treatments

Add to Reading List

Source URL: www.lsusd.lsuhsc.edu

Language: English - Date: 2009-06-26 12:06:08
59® Hard decisions about cancer 5 tests and treatments to question W

® Hard decisions about cancer 5 tests and treatments to question W

Add to Reading List

Source URL: mnoncology.com

Language: English - Date: 2014-12-30 11:16:00
60ASCO Annual Meeting - Chicago, IL, May 29 –June 2, 2015; Abstract #3017 Poster #: 343 A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. Jeffrey R. Infante1,

ASCO Annual Meeting - Chicago, IL, May 29 –June 2, 2015; Abstract #3017 Poster #: 343 A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. Jeffrey R. Infante1,

Add to Reading List

Source URL: www.armobio.com

Language: English - Date: 2015-12-11 00:15:33